Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: A randomized controlled study

R. B. Postuma*, A. J. Espay, C. Zadikoff, O. Suchowersky, W. R W Martin, A. L. Lafontaine, R. Ranawaya, R. Camicioli, A. E. Lang

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

48 Scopus citations

Abstract

Elevated homocysteine is associated with increased risk of heart disease, stroke, and dementia. Therapy of Parkinson disease (PD) with levodopa elevates homocysteine. The authors conducted a 6-week, multicenter, randomized, double-blind, placebo-controlled trial to test whether folate 1 mg/vitamin B12 500 μg or entacapone reduced serum homocysteine in 35 levodopa-treated PD patients. Levodopa initiation caused a small elevation in homocysteine. Vitamin therapy, but not entacapone, resulted in a decrease in homocysteine compared to placebo.

Original languageEnglish (US)
Pages (from-to)1941-1943
Number of pages3
JournalNeurology
Volume66
Issue number12
DOIs
StatePublished - Jun 2006

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: A randomized controlled study'. Together they form a unique fingerprint.

Cite this